JOJeremy E. Orr

Jeremy E. Orr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeremy E. Orr has a total of 278 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Obstructive sleep apnea-related hypoxemia and heart rate dynamics are associated with systemic inflammation in people living with HIV

    by Alexia N. Perryman, Jorge A. Masso-Silva, Jeremy E. Orr, Xiaoying Sun, Sonia Jain, Pamela N. DeYoung, Brynn Norby, Sonia Ancoli-Israel, Atul Malhotra, Igor Grant, et al.

  • Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide

    by Christopher N. Schmickl, Athiwat Tripipitsiriwat, Babak Mokhlesi, Monica Mallampalli, Brandon Nokes, Vaishnavi Kundel, Kathy Page, Christina Finch, Lucas Donovan, Mira Tadros, et al.

    Purpose Approximately one of ten US adults has comorbid obesity and obstructive sleep apnea (COBOSA). Traditionally, sleep medicine management of COBOSA focused on continuous positive airway pressure (CPAP). Recently, tirzepatide (a once-weekly injection) was approved for COBOSA after demonstrating substantial reduction of weight and OSA severity in efficacy trials. We assessed patient and provider attitudes towards these therapies for COBOSA. Methods We conducted an online survey (November 2024–August 2025) targeting US adults with OSA and/or obesity (“patients”) and sleep medicine providers. The survey assessed treatment acceptability, preferences, and informational needs. Results The analysis included 461 patients (86% with sleep apnea, 49% with COBOSA; ~5% response rate) and 114 providers. Overall, 70% of respondents found both CPAP and tirzepatide at least somewhat acceptable, with significantly different response patterns (P < .001): providers found CPAP more acceptable than tirzepatide, whereas patients rated both therapies similar. When asked to choose a preferred long-term therapy assuming equal effectiveness, patients favored tirzepatide (48% vs. 21%), while providers preferred CPAP (52% vs. 27%). Providers with experience prescribing injectable weight-loss medications were more aligned with patient views. Both groups supported combination therapy, though patients were less enthusiastic than providers (61% vs. 86%). Both groups valued a wide range of outcomes for decision making—across symptom, sleep, and cardiometabolic domains—and emphasized the importance of safety, long-term data, and costs. Conclusions Patients and providers view CPAP and/or tirzepatide as acceptable options for COBOSA, but preferences diverge. Given equipoise, comparative effectiveness trials are urgently needed to guide individualized treatment strategies.


  • Open Access

    Low Arousal Threshold Endotype and CPAP Adherence: Insights from a Large, Diverse Clinical Cohort

    by Christopher N. Schmickl, Christian D. Harding, Athiwat Tripipitsiriwat, Jeremy E. Orr, Andrey Zinchuk, Pamela DeYoung, Stacie Moore, Robert L. Owens, Scott A. Sands, Atul Malhotra

    Background: A low respiratory arousal threshold (ArTH) has been linked to reduced continuous positive airway pressure (CPAP) adherence in obstructive sleep apnea (OSA) via a multi-trait model developed in the RICCADSA trial. Our objective was to validate the prior model in a large, real-world cohort and explore alternative linear and non-linear approaches for predicting CPAP adherence. Research Question: Does a previously derived multi-trait model linking low ArTH to poor CPAP adherence remain valid in a diverse real-world population and do alternative linear or non-linear approaches offer improved predictive performance? Methods: Adults with OSA from the SNOOzzzE-cohort who initiated CPAP within 1 year of in-lab polysomnography (2017–2019) were included. Pathophysiological traits (Vpassive, Vactive, loop gain, ArTH, ventilatory response to arousal) were estimated from polysomnography. Poor (vs good) adherence was defined as ≤2.48h/night at month 1 (1 st sample quartile). The prior model’s performance was evaluated via the area under the curve (AUC) and adherence comparisons. Secondary analyses tested a de novo linear regression and a latent profile analysis (LPA)–derived trait-cluster model. Results: Among 744 participants (45% women, 47% non-White), median CPAP adherence was 4.8 h/night at 1 month. The prior model’s AUC was 0.51 (95%-CI 0.46–0.55), with no usage differences between predicted poor vs good adherers. A new linear model overfit in training (AUC=0.85) but failed in testing (AUC=0.55). LPA identified a “Low ArTH Driven” cluster with persistently lower adherence at months 2–3 (P<.05) and a “Low ArTH & High loop gain” cluster whose usage stabilized after month 1. Conclusions: The prior model did not generalize to this diverse clinical cohort. LPA identified a “Low ArTH Driven” endotype with persistently low CPAP adherence, suggesting potential for targeted interventions pending external validation.


  • Open Access

    Treatment Preferences For Comorbid Obesity and Obstructive Sleep Apnea (PRO-CON OSA) Survey: Patient and Provider Preferences for CPAP and/or Tirzepatide

    by Christopher Schmickl, Athiwat Tripipitsiriwat, Babak Mokhlesi, Monica Mallampalli, Brandon Nokes, Vaishnavi Kundel, Kathy Page, Christina Finch, Lucas Donovan, Mira Tadros, et al.

    Purpose Approximately one of ten US adults has comorbid obesity and obstructive sleep apnea (COBOSA). Traditionally, sleep medicine management of COBOSA focused on continuous positive airway pressure (CPAP). Recently, tirzepatide (a once-weekly injection) was approved for COBOSA after demonstrating substantial reduction of weight and OSA severity in efficacy trials. We assessed patient and provider attitudes towards these therapies for COBOSA. Methods We conducted an online survey (November 2024–August 2025) targeting US adults with OSA and/or obesity (“patients”) and sleep medicine providers. The survey assessed treatment acceptability, preferences, and informational needs. Results The main analysis included 461 patients (86% with sleep apnea diagnosis, 49% with COBOSA) and 114 providers. Overall, 70% of respondents found both CPAP and tirzepatide at least somewhat acceptable, with significantly different response patterns (P<.001): providers found CPAP more acceptable than tirzepatide, whereas patients rated both therapies similar. When asked to choose a preferred long-term therapy assuming equal effectiveness, patients favored tirzepatide (48% vs 21%), while providers preferred CPAP (52% vs 27%). Providers with experience prescribing injectable weight-loss medications were more aligned with patient views. Both groups supported combination therapy, though patients were less enthusiastic than providers (61% vs 86%). Both groups valued a wide range of outcomes for decision making—across symptom, sleep, and cardiometabolic health domains—and emphasized the importance of safety, long-term data, and costs. Conclusions Patients and providers view CPAP and/or tirzepatide as acceptable options for COBOSA, but preferences diverge. Given equipoise, comparative effectiveness trials are urgently needed to guide individualized treatment strategies. Current Knowledge/Study Rationale The weight-loss medication tirzepatide has recently emerged as a potential treatment option for patients with obstructive sleep apnea (OSA) and comorbid obesity (COBOSA), but little is known about patient and provider attitudes toward this therapy compared with the current first-line treatment of continuous positive airway pressure (CPAP) or what information they need to make informed choices between these options. Study Impact This survey demonstrates high levels of acceptability for both tirzepatide and CPAP, supporting clinical equipoise. It also highlights the priorities, concerns, and decision-making factors most relevant to patients and providers, providing a foundation for future comparative trials and implementation efforts that are aligned with stakeholder needs and preferences.


  • Opioids and Respiratory Related Consequences

    by Jeremy E. Orr, Deanna Hill, Robert L. Owens

  • Chronic pain is associated with sleep apnea severity but attenuated by intermittent hypoxemia in people using opioids

    by Jeremy E. Orr, Naa-Oye Bosompra, Brynn Norby, Jazmin Velazquez, Ahmed Khalaf, Pamela DeYoung, Christopher N. Schmickl, Scott A. Sands, Sonia Jain, Feng He, et al.

    Patients using long-term opioids for pain often have uncontrolled symptoms which might drive ongoing opioid use and contribute to the opioid public health crisis. Opioids also cause sleep disordered breathing (SDB), which might impact pain via arousals and hypoxemia, with potential for a vicious cycle. Adults with noncancer pain using opioids daily for >3 months were recruited. Subjects underwent pain and sleep questionnaires, pain tolerance via 10°C cold pressor testing, and polysomnography. Hypoxic burden was determined from polysomnographic signal analysis. Participants (n = 143) had a median (interquartile range) age of 60 (51, 67) years, body mass index 29 (25, 35) kg/m 2 . 80 (56%) subjects were female. The median daily morphine equivalent dose was 20 (10, 45). 78% had an apnea-hypopnea index (AHI) >5/hour and 41% with AHI >15/hour. PROMIS pain interference scores differed across SDB severity, with increased symptoms in mild and moderate but not severe SDB. With increasing AHI, there was worsened pain (β = 2.2 [95% confidence interval [CI]: 0.08, 4.4]; β std = 1.3; P = 0.043), but this relationship was attenuated at higher levels of hypoxic burden (per interaction; β = −0.42 [95% CI: −0.78, −0.06]; β std = −0.85; P = 0.023). During cold pressor testing, there was a reduced time to hand withdrawal with increasing AHI (hazard ratio [HR] 2.60 [95% CI: 1.48, 4.57]; P = 0.001), but this was also attenuated at higher hypoxic burden (HR: 0.86 [95% CI: 0.78, 0.94]; P = 0.002). Overall, SDB is linked with worsened pain in those using opioids for chronic pain, but hypoxemia attenuates the effect. Individuals with the same AHI may have different symptoms depending on hypoxic burden. Interventional studies will help elucidate mechanisms and the role for SDB treatment in pain management.

  • The combination of physiology and machine learning for prediction of CPAP pressure and residual AHI in OSA

    by Jui-En Lo, Christopher N. Schmickl, Florin Vaida, Shamim Nemati, Karandeep Singh, Scott A. Sands, Robert L. Owens, Atul Malhotra, Jeremy E. Orr

    Study Objectives: Continuous positive airway pressure (CPAP) is the treatment of choice for obstructive sleep apnea (OSA); however some people have residual respiratory events or require significantly higher CPAP pressure while on therapy. Our objective was to develop predictive models for CPAP outcomes and assess whether the inclusion of physiological traits enhances prediction. Methods: We constructed predictive models from baseline information for subsequent residual apnea-hypopnea index (AHI) and optimal CPAP pressure. We compared models utilizing clinical variables with those incorporating both clinical and physiological factors. Furthermore, we assessed the performance of regression versus machine learning. All performances, including root mean square error (RSME), R-squared, accuracy, and area under the curve (AUC), were evaluated using a five-fold cross validation with ten repeats. Results: For predicting residual AHI, random forest models outperformed regression models, and models that incorporated both clinical and physiological variables also outperformed models using only clinical variables across all performance metrics. Random forest using both clinical features and physiological traits achieved the best performance. In both regression and random forest models, central apnea index is found to be the most important feature in predicting residual AHI. For predicting CPAP pressure, there was no additional predictive value of physiological traits or random forest modeling. Conclusions: Our findings demonstrated that the combined use of clinical and physiological variables yields the most robust predictive models for residual AHI, with random forest models performing best. These findings support the notion that prediction of OSA therapy outcomes may be improved by more flexible models using machine learning, potentially in combination with physiology-based models.


  • The Pediatric to Adult Transition of Patients with Neuromuscular Disease

    by Jackie Chiang, Kathryn Selby, Jeremy Orr, Aaron Izenberg, Reshma Amin


  • Effect of obesity on sleep apnea pathogenesis differs in women versus men: multiple mediation analyses in the retrospective SNOOzzzE cohort

    by Brandon Nokes, Jeremy E. Orr, Stephanie White, Steven Luu, Zihan Chen, Raichel Alex, Scott A. Sands, Brian S. Wojeck, Robert L. Owens, Atul Malhotra, et al.

    Our data provide important insights into obesity-related obstructive sleep apnea (OSA) pathogenesis, thereby validating, and extending, prior research findings. This is the largest sample size study to examine the relationships between obesity and gender on OSA pathogenesis. The influence of obesity on sleep apnea severity is mediated by different mechanistic traits (endotypes).


  • Pathogenesis of sleep-disordered breathing in the setting of opioid use: a multiple mediation analysis using physiology

    by Jeremy E Orr, Atul Malhotra, Eli Gruenberg, Traci Marin, Scott A Sands, Raichel M Alex, Robert L Owens, Christopher N Schmickl

    Opioid medications are commonly used and are known to impact both breathing and sleep and are linked with adverse health outcomes including death. Clinical data indicate that chronic opioid use causes central sleep apnea, and might also worsen obstructive sleep apnea. The mechanisms by which opioids influence sleep-disordered breathing (SDB) pathogenesis are not established. Patients who underwent clinically indicated polysomnography confirming SDB (AHI ≥ 5/hour) were included. Each patient using opioids was matched by sex, age, and body mass index (BMI) to three control individuals not using opioids. Physiology known to influence SDB pathogenesis was determined from validated polysomnography-based signal analysis. PSG and physiology parameters of interest were compared between opioid and control individuals, adjusted for covariates. Mediation analysis was used to evaluate the link between opioids, physiology, and polysomnographic metrics. One hundred and seventy-eight individuals using opioids were matched to 534 controls (median [IQR] age 59 [50,65] years, BMI 33 [29,41] kg/m2, 57% female, and daily morphine equivalent 30 [20,80] mg). Compared with controls, opioids were associated with increased central apneas (2.8 vs. 1.7 events/hr; p = .001) and worsened hypoxemia (5 vs. 3% sleep with SpO2 < 88%; p = .013), with similar overall apnea–hypopnea index. The use of opioids was associated with higher loop gain, a lower respiratory rate (RR), and higher RR variability. Higher loop gain and increased RR variability mediated the effect of opioids on central apnea, but did not mediate the effect on hypoxemia. Opioids have multi-level effects impacting SDB. Targeting these factors may help mitigate the deleterious respiratory consequences of chronic opioid use.